BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...to MEK inhibitors, the PP2A activator decreased tumor volume compared with vehicle. Next steps by Rappta Therapeutics LLC...
...cancer (CRPC). TARGET/MARKER/PATHWAY: Protein phosphatase 2 (PP2A; PPP2CA), KRAS (K-Ras) LICENSING STATUS: Patented; licensed to Rappta Therapeutics LLC...
...Goutham Narla, Case Western Reserve University, Cleveland, Ohio email: gnarla@med.umich.edu Sandi Wong Array BioPharma Inc. Case Western Reserve University Rappta Therapeutics LLC University...
Items per page:
1 - 1 of 1
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...to MEK inhibitors, the PP2A activator decreased tumor volume compared with vehicle. Next steps by Rappta Therapeutics LLC...
...cancer (CRPC). TARGET/MARKER/PATHWAY: Protein phosphatase 2 (PP2A; PPP2CA), KRAS (K-Ras) LICENSING STATUS: Patented; licensed to Rappta Therapeutics LLC...
...Goutham Narla, Case Western Reserve University, Cleveland, Ohio email: gnarla@med.umich.edu Sandi Wong Array BioPharma Inc. Case Western Reserve University Rappta Therapeutics LLC University...
Items per page:
1 - 1 of 1